clinical trial · NCT05751941
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute·phase2·active not recruiting·n = 26
Prostate CancerMetastatic Prostate CancerAbirateroneEnzalutamideApalutamideSipuleucel-T
brief summary
This study is designed to test the hypothesis that using Sipuleucel-T (Provenge) in combination with new hormonal agents (NHA) (abiraterone, enzalutamide, apalutamide) for the treatment of participants with asymptomatic metastatic castration resistant prostate cancer (mCRPC) and no visceral metastases would enhance the activation of antigen presenting cells (APC) by sipuleucel-T.
started
Feb 14, 2023
primary completion
Jul 4, 2026
completion
Dec 1, 2026
last updated
Sep 15, 2026
official title
A Phase II Randomized Study of Sipuleucel-T With or Without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer With PSA Progression While on NHA and LHRH Analog
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol